Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

-- Advances 5x30 strategy by expanding pipeline with a highly complementary asset that has the potential to provide several days of pain control --

-- Phase 2 program for AMT-143 expected to begin in 2026 --